tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: Leap Therapeutics (LPTX), Viridian Therapeutics (VRDN) and Oyster Point Pharma (OYST)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Leap Therapeutics (LPTXResearch Report), Viridian Therapeutics (VRDNResearch Report) and Oyster Point Pharma (OYSTResearch Report) with bullish sentiments.

Leap Therapeutics (LPTX)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Leap Therapeutics on September 13 and set a price target of $5.00. The company’s shares closed last Tuesday at $2.40.

According to TipRanks.com, Beatty is a 4-star analyst with an average return of 7.9% and a 50.5% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Leap Therapeutics with a $4.83 average price target, implying a 100.4% upside from current levels. In a report issued on October 4, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $6.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Viridian Therapeutics (VRDN)

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics on November 5 and set a price target of $31.00. The company’s shares closed last Tuesday at $18.78.

Katkhuda has an average return of 18.9% when recommending Viridian Therapeutics.

According to TipRanks.com, Katkhuda is ranked #7540 out of 7727 analysts.

Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $35.33, which is an 86.9% upside from current levels. In a report issued on October 21, Wedbush also maintained a Buy rating on the stock with a $30.00 price target.

Oyster Point Pharma (OYST)

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Oyster Point Pharma on November 5 and set a price target of $53.00. The company’s shares closed last Tuesday at $11.54, close to its 52-week low of $10.00.

According to TipRanks.com, Dolezal is ranked #6821 out of 7727 analysts.

Oyster Point Pharma has an analyst consensus of Strong Buy, with a price target consensus of $38.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LPTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed